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Summary Interleukin 3 (IL-3) is produced constituitively by WEHI-3b leukaemic cells and stimulated
lymphoid cell populations in vitro. We have investigated the in vivo production of IL-3 in mice rendered
leukaemic with WEHI-3b cells and mice stimulated by acute graft versus host disease (GVHD). In leukaemic
mice, IL-3 was not found in serum or sonicates of 18-day spleens or bone marrow, although cells from the
leukaemic organs were fully competent to elaborate IL-3 in vitro. Further, elaboration of IL-3 by WEHI cells
in vitro was not affected by co-culture with normal haemopoietic cells. However, intracellular IL-3 was
detected in leukaemic nodules isolated from the liver. Inhibitors specific for IL-3 were not found, although
liver-cell conditioned medium and leukaemic nodule sonicates contained potent non-specific inhibitors of cell
growth. At 21 days, intracellular IL-3 was also present in spleens and correlated with the presence of non-
specific inhibitors. In GVHD, no evidence for IL-3 elaboration in vivo was found, nor did lymphoid
populations affected by GVHD spontaneously elaborate it in vitro; however, their competence to produce it
was unaffected, as IL-3 was elaborated on subsequent mitogen stimulation in vitro.
We also investigated the recovery and circulation of in vitro ...Indium-labelled IL-3 dependent cells after
injection in vivo and the half-life of semi-purified IL-3. Dependent cells were not recovered after injection into
irradiated recipients, although the cells recirculated for at least 24 hours. Inability to recover dependent cells
was explicable on general cytotoxicity which masked potential recovery. The serum half-life of injected
partially purified material with IL-3 activity was short (<30min). We conclude that the elaboration of IL-3
by leukaemic WEHI-3b is not an in vitro artifact and these results are discussed in relationship to other
growth factors and the leukaemic state, and the origin of IL-3 dependent lines.
The myelomonocyte leukaemic cell line WEHI-3b
(Warner et al., 1969) is unusual in that it elaborates
constituitively a number of biologically active
factors such as mast-cell growth factor,
megakaryocytic progenitor cell stimulator,
granulocyte/macrophage stimulating factor and
erythroid burst promoting activity, (but not
Interleukin 2) (Metcalf, 1981; Yung & Moore,
1982; Iscove et al., 1982; Larsson et al., 1980).
Recently, we have reported the establishment in
vitro of a number of murine cell lines termed
Factor-Dependent Cell Lines (Paterson) (FDCP)
whose growth depends absolutely on a factor
[haemopoietic cell growth factor (HCGF)]
contained in media conditioned by the growth of
WEHI-3b cells (WEHI-3bCM) (Dexter et al., 1980).
It is also found in supernates from poke-weed
mitogen-stimulated spleen cells, where it requires
the presence of T cells for its elaboration (Garland
& Dexter, 1982a). The cell lines appear to be
myeloid since they exhibit myeloid morphology and
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cytochemistry, and express surface Mac-I and
F4.80 antigens (Garland & Dexter, 1982b; Garland
et al., 1982); antigenically, they bear resemblance to
WEHI-3b cells. Somewhat similar cell lines have
also been described by Greenberger (1980) and
Hapel et al. (1981) in the latter case classified as
lymphoid largely on the criteria of Thy antigen and
expression of 20a steroid dehydrogenase (Ihle et al.,
1982). The factor promoting these "lymphoid" lines
has been termed "Interleukin-3" (IL-3) and appears
to be the same as HCGF (reviewed in Garland &
Dexter, 1983); both activities are associated with a
28-3OKd glycoprotein (Bazill et al., 1983; Ihle et al.,
1982) and purified IL-3 optimally promotes FDCP.
Additionally, HCGF and IL-3 promote the
proliferation of multipotential stem cells, (Bazill et
al., 1983; Garland & Crompton, 1983) and
basophil/mast cells in vitro (Schrader et al., 1981; J.
Ihle, personal communication). The existence of
FDCP thus provides a ready and sensitive assay for
IL-3. The phenotypic similarity of IL-3 requiring
FDCP to the IL-3 producing leukaemic WEHI-3b
line raised the intriguing possibility that they were
related, the leukaemic state being associated with
the endogenous, constituitive production of a
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growth factor operative on a number of
haemopoietic cell lineages in vitro. For this to be
true, it would be necessary to show that IL-3 was
made in vivo and existed in measurable amounts
particularly in the cytoplasm of leukaemic cells;
that is, it is not an in vitro artifact. Further, it may
be asked (i) is IL-3 involved in the regulation of
normal cells, as its origin from stimulated lymphoid
populations would suggest, and (ii) are FDCP also
representative of a normal cell population?
We have tried to answer these questions by firstly
seeking the activity in situations induced in vivo
which parallel those in vitro where IL-3 is
produced: namely during the pan-lymphocyte
stimulation associated with acute graft versus host
disease (GVHD)-a parallel of mitogen stimulation
(Ford et al., 1981); and in mice rendered acutely
leukaemic after transfusion with WEHI-3b cells.
Secondly, we have followed the fate of FDCP cells
after injection into normal and irradiated mice.
Throughout this study and in the absence of any
indication that factors other then IL-3 (or HCGF)
promote FDCP, we have equated FDCP
stimulatory activity with the presence of IL-3.
Materials and methods
Induction of WEHI-3b leukaemia and cell culture
WEHI-3b cells were cultured in Fischer's medium
(Gibco Biocult) supplemented with 10% horse or
foetal calf serum (Gibco Biocult). For leukaemia
induction, syngeneic Balb/C mice were injected i.v.
with 105, 106 or 107 washed WEHI-3b cells. The
mice were inspected daily and when showing signs
of leukaemia were killed and the serum collected.
Suspensions of the spleen cells were made by
teasing, and of the bone marrow by aspirating the
femoral cavity with a syringe. Resulting suspensions
were cultured at 104 cellsml-1 in RPMI 1640
(Gibco Biocult)/10% FCS for 3 days at 370 in 5%
CO2. Leukaemic nodules in the liver were dissected
out individually, and weighed before teasing and
sonication. Representative livers were also fixed in
Bouin's solution for leukaemic nodule estimations.
Induction ofGVHD
Parental strain spleen cells (106) from C57B1/6 mice
were injected i.v. into B6D2F1 recipients. At
various intervals, a number of mice (6 per group)
were sacrificed. After collecting and pooling the
serum, the spleens were weighed and a small
fragment fixed in glutaraldehyde for sectioning.
Three of the remaining spleens were dissociated and
a single cell suspension was made. After red-cell
lysis in hypotonic conditions, 106 cellsml-1 were
cultured in RPMI/10% FCS with and without 1%
Poke-weed mitogen (Gibco Biocult) at 370 in 5%
CO2 for 3 days.
Assayfor IL-3
The factor dependent lines FDCP-7,-2, and
Al.1.1.C2 were used as indicators. All are non-
adherent granulated cells, maintained in
Fischer's/10% FCS supplemented with 10%
WEHI-3b conditioned medium (CM). The lines
respond optimally to purified IL-3, (kindly
provided by Dr. J. Ihle). Washed FDCP (105) were
plated in triplicate in 0.2ml final volume
Fischer's/10% FCS, containing serial dilutions of
assay material. After incubation overnight at 370,
1 pCi per well Tritiated thymidine [3H]dT.
Radiochemical Centre, Amersham) was added to
each well, and the cells harvested on to glass fibre
mats after 3h incubation. Counts were measured by
scintillation counting. Controls consisted of WEHI-
3b conditioned medium at the optimal
concentration of 10% for FDCP-7; A1.1.1.C2 is
slightly more sensitive, with an optimal
concentration of 2.5%; uptake of [3H]dT was
significantly reduced below these concentrations.
Test material was also assayed in 10% (or less as in
the text) WEHI-3b CM to determine the presence
of inhibitors. Controls of FDCP cells in medium
alone were always included.
For viability assays, an equal volume of Trypan
Blue solution (0.5% in saline) was added to an
aliquot of cell suspension, and the proportion of
dead cells counted.
Preparation ofassay samples and cell sonicates
Cell supernates were assayed after centrifugation at
3000 rpm to remove cells followed by 0.22p
millipore filtration. Sonicates were prepared by
lysing 5 x 106 to I07 washed nucleated cellsmlP- on
ice using 20 second bursts of ultrasound (MSE
ultrasonicator 6-12p peak height). All sonicates
were checked for breakage, the debris spun out at
20,000rpm (30,000g) for 1 h and then sterilised by
Millipore (0.22p) filtration.
Colony assays
For estimation of bone marrow granulocyte-
macrophage progenitors (G/M-CFUc), 5 x 104
marrow cells were plated in 1 ml of Fischer's
medium plus 10% horse or FCS supplemented with
0.5% Bacto agar (Difco Ltd) and 20% v/v mouse
heart conditioned medium (as a source of
granulocyte/macrophage colony stimulating factor,
G/M-CSF) in 3 cm diameter plastic petri-dishes.
Plates were set up in triplicate and counted after 5
or 7 days incubation at 37° in an atmosphere of 5%IL-3 AND FDCP IN VIVO 249
CO2 in air. Colonies containing >50 cells were
scored under direct illumination with a colony-
counting microscope. For estimation of WEHI-3b
clonogenic cells, between 1 and 5x 104 cells were
cultured as above, omitting the heart conditioned
medium.
Cell recirculation studies-Indium labelling
The FDCP line A2C2, aThyl negative, Mac-I and
F4.80 positive cell line was used. Cells were
washed free of serum and incubated in serum-free
RPMI at 106 cellsml-1 with 10,uCi "'lIndium
Oxime (Radiochemical Centre Amersham, Sp.Act.
370MBq/pgln) per 108 cells (Thakur et al., 1977).
Cells were washed 3 times to remove non-chelated
isotope, and 107 cells per mouse injected into
normal and irradiated syngeneic recipients via the
tail vein. At various time intervals, whole organs
(Thymus, Liver, Spleen, Gut, Femur and Lungs)
were removed and counted in a y-scintillation
counter. At least 2 mice per time point were used,
and 1l'Indium labelled normal marrow or lymph-
node cells used as controls. Results are expressed as
% counts in each organ of the total cumulative
counts. The total recovery of label in marrow, gut,
lungs, thymus and liver was between 60 and 65% at
24h.
Suppression ofFDCP and absorption ofIL-3 activity
by liver cells in vitro
(a) Effect of liver cells on FDCP
proliferation: FDCP cells (105 per well) were co-
cultured with various ratios of irradiated liver cells
obtained by mechanical dissociation, in
Fischer's/FCS medium with 10% WEHI-3b CM.
After 24h, cell proliferation was assayed by
[3H]dT. In parallel, FDCP were assayed for clonal
growth in agar in the presence of WEHI-3b CM
and various ratios ofliver cells.
(b) Absorption of IL-3 activity: normal liver
fragments were treated with collagenase (Type IV,
SIGMA, 10 ugml' for 1 h at 37°C followed by
gentle trypsin digestion (0.025% Trypsin in 0.005%
EDTA) for 1h at 370C. Remaining clumps were
mechanically dissociated, after termination of
trypsin treatment by addition of 10% FCS.
Approximately 1 liver equivalent of dissociated liver
was centrifuged at lOOrpm for 15min and the cell
pellet retained. The supernate was centrifuged at
40,000rpm (100,000g) for 1 h. Both cell pellets and
supernate were separately incubated with 5ml 50%
WEHI-3b CM at 37°C. Samples were removed at
known intervals, centrifuged at 10,000g for 4min,
filtered and titrated for IL-3 activity against an
FDCP line and a factor-independent line, 15al, for
non-specific toxicity.
Co-culture of WEHI-3b cells with normal
haemopoietic cells
Washed WEHI-3b cells (104ml-') were co-cultured
with 104, 105 or 106ml-1 normal marrow or spleen
cells. Samples of the supernates were withdrawn
daily, filtered and assayed for IL-3 activity at 10%
concentration.
Half-life ofIL-3 activity in vivo
A preparation of partially-purified factor with very
high IL-3 activity was kindly provided by Dr. G.
Bazill (Bazill et al., 1983). An amount equivalent to
approximately 10ml WEHI-3b CM (active at 10%)
was injected i.v. into a number of normal mice
from which serum was collected at known intervals
by heart puncture.
Cell lines
FDCP-7 and -2 have been previously described
(Dexter et al., 1980; Garland & Dexter, 1982a). The
lines A2C2 and A1.I.1.C2 are Thyl.2 negativc
FDCP generated from long-term bone marrow
culture (LTBMC) at 4 weeks (Garland & Dexter,
1982). All the cell lines are promoted by IL-3 and
are refractory to T cell growth factor, GM/CSF
and other known cell proliferation factors (Garland
& Dexter, 1982b). The cell line 15al is a sub-clone
of the factor-independent line 416B, also derived
from LTBMC (Dexter et al., 1979).
Fractionation ofIL-3 activity on Biogel P30
Samples (0.2ml) were fractionated on a 28 x 1.2cm
diameter Biogel P30 (Biorad Labs Ltd)
polyacrylamide column equilibrated in PBS (0.85%
NaCl; 0.01 M phosphate) and run at 2mlhr- at
room temperature. Fractions of 0.32ml were
collected and assayed at a final concentration of
25%. The column was calibrated with /
lactoglobulin (M.W. 35 Kd) and horse myoglobulin
(M.W. 18,800Kd) (Sigma).
Proliferative response of WEHI-3b cells to IL-3
All media was warmed and all operations carried
out at 37°C to avoid cold shock. An actively-
growing culture of WEHI-3b in Fischer's 10% FCS
was obtained by subculture 48h previously at low
cell density (5 x I04ml-1). The culture was
centrifuged gently (800rpm, 5min) resuspended in
sufficient Fischer's/10% FCS to yield a density of
106 cellsml-1, divided into 2 equal portions and
centrifuged as before. One portion was resuspended
in fresh Fischer's/10% FCS, the other in the
original supernate at 50% v/v, and both returned
for re-incubation. At various times, an equal
aliquot was removed from each, and assayed for250 J.M. GARLAND et al.
[3H]dT incorporation (triplicate wells, i0 cells per
well, 1 h exact pulse time at 5 uCiml- 1), cell count,
and cell viability by Trypan blue. Results are
expressed as the percentage of the values for each
culture at the beginning of the re-incubation.
Animals
C57B1/6 and (C57bl6 x DBA/2)F1 mice were
obtained from the Paterson Laboratories Animal
Unit.
Results
IL-3 activity in the mice undergoing acute GVHD
Mice were sampled at various times after GVHD
induction. No activity was found in the serum at
any stage, and titration of pooled GVHD serum
showed no significant inhibition of IL-3 responses
at levels below 20% serum (see below). Spleen cells
were then cultured with and without PWM, and the
supernates tested for IL-3 (Table I). No activity
was found when the cells were cultured alone, but
at all stages of GVHD, as indicated by spleen
index, high concentrations of IL-3 were induced by
PWM in vitro which titrated down to 5% CM or
less. Thus, the cells were still competent to make it.
Histology of the spleens at these time-points
showed pathologies consistent with moderate to
severe GVHD reactions.
Table I IL-3 activity in spleen-cell conditioned media
from mice undergoing GVH reactions, measured by
[3H]dT incorporation
-PWM" +PWM
% of % of
Time Spleen indexa control control
Day 2 1.21+0.27 3c (N.S.) 148
4 1.52+0.38 2 (N.S.) 137
6 2.1 +0.21 8 (N.S.) 72
10 1.74+0.63 4 (N.S.) 87
15 1.81+0.23 3 (N.S.) 120
aIndex
Experimental spleen mass/Experimental mouse mass
Control spleen mass/control mouse mass
bCells from 3 pooled spleens were cultured 3 days with
and without PWM.
cFigures are percent of a normal control stimulated with
PWM N.S.=not significantly different from control
without PWM by x2 test. Activity was assayed on the
FDCP-2 line, using a dilution of 25% v/v supernates.
Absolute levels of [3H]dT incorporations in the positive
controls were similar to those described elsewhere
(Garland & Dexter, 1982a) and in the range 18-
30,000cpm 10- cells.
IL-3 activity in WEHI-leukaemic mice
(a) Establishment of leukaemia The cloning
efficiency of cultured WEHI-3b cells in agar was
-3%, however, this value varied between 0.3 and
6%. With any given culture, clonogenicity in agar
was linear between 104 and 105 cells per plate.
Below 104 cells there was progressive loss of
colonies; above 105 cells counting was difficult
because of high background and the presence of
many small cell clusters (10-50 cells). Generally at
least iOs WEHI-3b cells per mouse were required
for leukaemia induction. Most mice injected with
106 WEHI-3b cells died of their leukaemias within
23 days and had greatly enlarged, smooth spleens.
The liver also had numerous surface nodules. The
numbers of clonogenic cells in marrow and spleens
at various injected doses of cells were determined at
different times. Table II shows that at 18 days the
numbers of clonogenic cells in leukaemic organs
was dose-dependent on injected WEHI-3b cells and
further that the cloning efficiency had increased;
therefore, experiments were standardised to 106
injected WEHI-3b cells per mouse. With 106
injected WEHI-3b cells most, if not all, the
clonogenic cells in 18-day spleens and marrow were
WEHI-3b cells, as shown by similar numbers of
colonies in the presence and absence of heart-
conditioned medium (Table II). The relative absence
of normal progenitors responding to G/M CSF in
leukaemic organs was explicable on their dilution
by leukaemia cells, although they were still present
(Table II, 105 injected WEHI-3b cells). Thirty
individual agar colonies were picked at random
from leukaemic spleens and sub-cultured. All clones
grew spontaneously and made IL-3. Three cultures
were karyotyped and had karyotypes of WEHI-3b
Table II GM-CSF-dependent and -independent coloniesa
from 18-day WEHI-3b leukaemic marrow and spleen
Colonies at
Colonies/3 x 104 8 days
with without
Source ofcells GM-CSFb GM-CSF
Normal marrow 21+4.7 0
WEHI-3b culture 122±15 89+ 15.5
Marrow, + 105 injected
WEHI-3b cells 7.6+3 0
Marrow, + 106 injected
WEHI-3b cells 158+11.4 144+59
Spleen, 105 injected
WEHI-3b cells 200+51 127+34
Spleen, + 106 injected
WEHI-3b cells 200+ 200+
aCells were plated in semi-solid agar. Counts given for
mean colonies per plate + ls.d.
bHeart conditioned medium at 20%.IL-3 AND FDCP IN VIVO 251
cells (68-73 acrocentrics and one dicentric
chromosome). Thus, leukaemic marrow and
particularly spleen, had very high numbers of
WEHI-3b cells capable of producing IL-3 in vitro;
based on the cell counts and cloning efficiencies,
such leukaemic spleens were calculated to contain
at least 85% WEHI-3b cells at 18 days. In the liver,
discrete large nodules occurred; cytologically they
consisted of virtually pure populations of cells with
WEHI-3b morphology. At 18 days, an average of
95 nodules per liver were counted.
E
0.
0
x 18 day leukaemic serum + 10% WECM
o NMS + 10%h WECM
* 18 day leukaemic serum
(b) IL-3 activity in leukaemic serum Examination
of the serum from leukaemic mice showed firstly
that no IL-3 activity was present at any stage of the
disease (Table III). This could be due to inhibitors
present in the serum. However, titration curves
showed that neither normal nor leukaemic serum
significantly inhibited the responses of FDCP to
IL-3 (Figure 1) below 10% leukaemic serum
concentration in the presence of optimal IL-3
concentrations. Nor was inhibition seen at sub-
optimal levels of IL-3 (2.5%). Thus, failure to
detect IL-3 in leukaemic serum was not due to the
presence of overt inhibitors.
Table III IL-3 activity in seruma from WEHI-3b
leukaemic mice
Time after
Injection No. leukaemic cells injectedper mouse
(days) iOs 106 1O7
7 2,885+674b 3,044+510 2,669+ 177
14 2,870+651 2,396+82 4,238+1,544
18 2,428+277 2,076+251 2,384+406
Control cells+WEHI CM 10% 36,582+2,087
Control cells-WEHI CM 2,616+290
aSerum was used at 5% final concentration (see Figure
1).
b[3H]dT incorporation in standard assay, cpm+s.d.
using FDC-P7.
(c) Half-life of IL-3 in vivo A lack of detectable
serum IL-3 could be explained by rapid serum
clearance. To test this, a concentrated, partially
purified IL-3 (equivalent to - IO ml WEHI-3b CM
active at 10%) was injected i.v. into a number of
mice, and the serum collected at various intervals
(Figure 2). This serum was then compared with
serum to which 2.5% WEHI-3b CM had been
added. Whilst activity was present at 10min post-
injection, none was detected at 1 h. The reduction
in activity after 10min in vivo compared to serum
in vitro extrapolates to a half-life of <30min.
% serum
Figure 1 IL-3 activity in serum of leukaemic mice.
Dilutions of serum were assayed against FDCP-7 cells.
Control normal serum without WEHI-3b CM gave
values closely similar to leukaemic serum; however, the
control levels of [3H]dT incorporation in this
experiment were higher than normally found, see Table
III.
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Figure 2 IL-3 activity in serum of mice injected i.v.
with semi-purified IL-3. (A A) serum dilutions in
the presence of2.5% WEHI-3b CM (Control). (El
Ol) serum dilutions 10min after injection in vivo (no
WEHI-3b CM). No activity in injected serum was
demonstrable after 1h. Activity was measured by
[3H]dT incorporation by FDCP-7; background
incorporation without WEHI-3b CM was <2000cpm
(in the presence of control serum).
Therefore, the absence of detectable IL-3 in
leukaemic serum could be partially accounted for
by its very short half-life in vivo.
(d) Detection of intracellular IL-3 in leukaemic
organs With the above result, it was decided to
determine if IL-3 was in fact made in vivo at all.
WEHI-3b produces IL-3 constituitively in vitro and
its presence intracellularly was readily demonstrable
in centrifuged sonicates of washed WEHI-3b cells
(Table IV) However, when similar numbers of 18-
day leukaemic spleen cells were sonicated, no
-. -- nL
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Table IV Intracellular IL-3 in sonicates of WEHI-3b cells grown in vitro and in vivo:
comparison with IL-3 in WEHI-3b conditioned medium
% ofcontrol countsb
Cell no. % sonicate in sonicate:
equivalent/ml in testa without with 10%
Cellpopulation ofsonicate v/v WEHI-3b CM WEHI-3b CM
WEHI, in vitro 2.3 x 107 50 78 ND
12.5 49 ND
Leukaemic marrow 1 0.8 x 107 50 2.6 105
(18 days) 2 107 50 1 73
Leukaemic spleen 1 4.3 x 107 50 1 72
(18 days) 2 4 x 107 50 1 93
Leukaemic nodules 2.5 x 107 6 5.3 4.6c
in liver
(18 days) 3 30 44
aSonicates assayed on FDCP.
bControl counts=cell grown in 3% WEHI-3b CM (1%
above optimum concentration).
cLeukaemic nodules were assayed on FDCP Al.l.l.C2.
See Table VII also.
activity was detectable in the sonicates either by
viability estimations on, or [3H]dT incorporation
by, FDCP indicator cells. Table IV also shows that
at a 5-fold excess of centrifuged sonicates over
WEHI-3b CM none of the sonicates from
leukaemic spleen and marrow contained substances
inhibiting the assay (see below). Further, in the
absence of WEHI-3b CM, residual [3H]dT
incorporation by FDCP was maintained showing
that the sonicates were not directly toxic to the
cells. That cells from leukaemic organs were still
able to elaborate the factor was shown by
incubating small numbers of leukaemic spleen cells
(104ml-') in vitro, when M6L-3 was again readily
detectable in the culture supernates (Table V).
Further, normal spleen and marrow cells did not
inhibit the production of, or markedly absorb, IL-3
in vitro as shown in Table VI; very high
Table V IL-3 activity in conditioned medium from 18-
day leukaemic spleen or marrow, cultured 3 daysa in vitro
Cultured Cultured
% concentration CM spleenb CM marrow CM
20 36,530+4,314 42,978+1,822
5 23,462+5,136 22,073+1,293
1 17,579+2,139 11,465+1,426
Control medium with 10% WEHI-3b
CM 36,582+2,087
Control medium without WEHI-3b CM 2,616±290
aWithout mitogen. No activity was present in normal
spleen or marrow cultures without mitogen.
bCounts given for mean cpm+ ls.d.
concentrations of normal spleen and marrow cells
were co-cultured with WEHI-3b cells without
producing a significant drop in IL-3 titre,
particularly during the early synthetic phase when
inhibition or absorption would have greatest effect.
It was therefore important to determine if this
apparent lack of IL-3 synthesis in vivo was common
to all leukaemic cells regardless of anatomical site.
Sonicates of leukaemic nodules from the livers at 18
days contained significant IL-3 activity but it was
masked at high sonicate concentrations by
inhibitors (Table IV). The level of activity in
sonicates was approximately 5-fold less than that in
a similar quantity of WEHI-3b cells grown in vitro.
Thus, liver nodule sonicates contrasted with those
from leukaemic marrow and spleen in the presence
of both IL-3 and inhibitors. Having demonstrated
production in vivo of IL-3 within compact WEHI-
3b colonies, mice were taken to 21 days and spleen
and marrow sonicates examined for IL-3 (Table
VII). In contrast to the previous results, IL-3
activity was now detectable in spleen sonicates, but
the levels were low (more than 10-fold lower than
in in vitro sonicates) and there was indication of the
presence of inhibitors. To determine whether the
inhibition was specific to IL-3 dependent cells, the
same sonicates were titrated against the factor-
independent haemopoietic cell line 416B. The
results showed that the inhibition was not specific
as the factor-independent line was also inhibited
(Table VII). Visual examination of the wells
showed that the [3H]dT incorporation reflected cell
viability and proliferation and not competition for
isotope by small molecular weight nucleotides
released during sonication.IL-3 AND FDCP IN VIVO 253
Table VI Normal spleen and marrow cells do not suppress in vitro production of WEHI-3b
cell derived IL-3
No. spleen marrow No. co-cultured Day 1 S-N Day 2 S-N
cells ml-1 WEHI cellsml-1 Marrow Spleen Marrow Spleen
104 104 2,833+218 3,309+149 9,187±620 6,011+737
S0, 104 3,223+96 2,975+195 7,709+1,213 7,771+588
106 i04 3X078+67 4,153+263 9,332+367 1,1051 + 1,638
0 (control) 104 3,309+395 579+739
0 (Control without
IL-3) 0 1,377+334
10% WEHI-3b CM
control 18,862+1,971
Day 3 assay samples showed levels of IL-3 activity equal to 10% standard WEHI-3b CM in
cell supernates (S-N).
Table VII Intracellular IL-3 in sonicates of 21-day leukaemic nodulesa and spleensb
Spleen + 416B+ 416B+
Liver nodule + 5% WEHI-3b liver spleen
% sonicates Liver nodule 3% WEHI-3b CM Spleen CM sonicates sonicates
12.5 1,201+186 1,274+100 3,586+686 7,898+640 570+367 34,366+2,646
6 2,716+181 2,358+286 8,409+ 1,028 16,678+842 481+16 52,312+4,288
3 14,976+1,049 22,157+466 6,856+354 19,094+ 1,575 2,781 +342 65,187+2,775
1.5 10,286+2,600 39,634+ 1,138 4,241+511 21,728+954 30,760+8,723 61,432+3,208
S-480-3 control 50,435 +6,386 28,114+888
S-480-3 control no. 1,544+41 910+34
WEHI-3b CM
416B control 74,698+ 139
aSonicates were assayed on FDCP line A1.1.1.C2. Individual leukaemic nodules were dissected out from the liver; a
total of 160mg wet weight, equivalent to 5 x 107 cells, were used in 2ml.
bFigures are for one 700mg wet weight spleen, equivalent to - 5 x 108 cells, in 2ml.
cFigures are given for cpm +s.d. on duplicate wells.
Molecular weightfractionation ofin vivo IL-3
It was possible that in vivo IL-3 activity was
associated with a molecular species different from
in vitro IL-3. Liver nodule sonicates were therefore
fractionated on Biogel P30, the elution pattern
being compared with that of WEHI-3b CM and
a preparation IL-3. IL-3 eluted with an apparent
average mol.wt of 28Kd, (Figure 3) but recovery
was low; -80% was irreversibly bound (2
experiments). However, a similar mol.wt average
for IL-3 has recently been given (Ihle et al., 1982).
In common with previous experience (Bazill et al.,
1983) WEHI-3b CM eluted over a broader slightly
higher mol.wt range with an average of 32Kd
(mean peak height). Liver sonicate activity eluted
almost identically to IL-3 (with an enhanced
shoulder at 32Kd). The elution characteristics of
the in vivo activity therefore were closely similar to
IL-3 and WEHI-3b CM.
Studies on the circulation ofFDCP
We wished to know if factor-dependent cells
represented a normal cell population. Experiments
were therefore performed to determine if cells from
a dependent line were viable after injection into (a)
normal and (b) lethally (8.5 Gy) irradiated
recipients, in (b) recognising them by their ability to
subsequently grow in WEHI-3b CM supplemented
agar or liquid culture. When up to 107 FDCP-1
cells were injected per irradiated mouse, none could
be recovered from marrow or spleen even after
30min post-injection and up to 24h later. It was
possible that the FDCP were rapidly killed in vivo,
and therefore studies were undertaken in which an
FDCP line (A2C2) with a "half-life" (by [3H]dT
incorporation) of about 15h in the absence of IL-3
was labelled with non-reutilisable t1l'ndium and
the cell's circulation in normal and lethally
irradiated mice followed. The results are given in254 J.M. GARLAND et al.
Figures 4 & 5. Firstly, normal marrow cells were
used as controls in normal mice (Figure 4); these
showed a rapid traffic of label between spleen and
lungs over the first 8h. Only small numbers of cells
(<2%) were found in the marrow, and virtually
none in thymus. Most cells apparently lodged in the
liver eventually (at -12h). The circulation of
FDCP, was, however, quite different (Figure 5).
There was progressive re-circulation from the lungs
to both spleen and liver; this continued over a
period of nearly 20h, and was not complete until
after this time. Approximately the same number of
FDCP lodged in the marrow, gut and thymus as
normal marrow cells. Similar results were recorded
in lethally-irradiated recipients (data not shown).
Thus, although no FDCP were recovered in the
previous experiments the cells were still
recirculating in vivo.
Tube no.
Figure 3 Fractionation of IL-3 activities on Biogel
P30 polyacrylamide column. Samples were eluted with
PBS. The void volume as estimated by blue dextran
dye was 4.6ml, at position 14/15. Markers are given
for ,B-lactoglobulin and horse myoglobin (35 and
18,800Kd). Recoveries were >80% for WEHI-3b CM
and liver sonicate; recovery of IL-3 was 20%.
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Suppression ofFDCP by liver cells in vitro
Since the above data showed that FDCP were
arrested in the liver, we determined whether liver
cells could suppress FDCP or metabolise IL-3 in
vitro. In the first experiments, FDCP were mixed
with various ratios of normal and irradiated liver
cells in an agar colony assay. At ratios of 1
Normal BMC"l In labelled cells
50
,Lungs
Figure 4 Recirculation of ...Indium-labelled normal marrow cells in normal mice cells. Note reciprocal
exchange between spleen and lungs at 2-4 hours post-injection. Points given for mean counts +s.d.
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Figure 5 Recirculation of "1'Indium-labelled FDCP (line A2C2) in normal mice. Compare with Figure 2.
Note progressive accumulation of counts in liver and spleen and reciprocal loss from lungs.
FDCP: 2000 liver cells, colony formation was
completely inhibited, (Table VIII) although at lower
ratios (1:400) colonies were observed. In WEHI-3b
CM supplemented liquid culture, FDCP apparently
survived for at least 2 days as judged by phase
microscopy when co-cultured with ratios of 1:1000
and 1: 5000 liver cells, but despite repeated
subculturing, none were subsequently recovered.
These results could be due to absorption of the IL-
3 by liver cells. Initial results using unseparated
liver suspensions to absorb WEHI-3b CM
suggested that IL-3 activity was very rapidly lost
(none at 4h incubation). Experiments were therefore
performed using liver suspensions separated by
centrifugation into a cell-free supernate and two
sizes of pellet. These were used to absorb excess
and sub-optimal amounts of IL-3, the supernates
being titrated against both an FDCP line and a
Table VIII Suppression of FDCP colonies in agar by
normal liver cells
No. colonies
Ratios ofFDCP to liver cells? at 7 days
1:25x10 0
1:6.4x104 0
1:800 106+9
1 :0 Control >500
'5 x 104 FDCP2 cells plated.
factor-independent line, 15al. Titrations of the
absorbed supernates showed that by both [3H]dT
assay and viability estimation, considerable
inhibitory activity on both the FDCP line and 15al
factor-independent line was present in all samples
after 2h incubation particularly in the 100,000g
supernate. However, the IL-3 activity was
unchanged and re-appeared at higher dilutions of
supernates (Table IX). As the viability of the initial
liver cells suspensions was low (15-20%), these
results show that in vitro neither liver cells nor their
released contents contain degradative enzymes or
inhibitors specific to IL-3 and the inhibition of
FDCP cells in vitro previously found with liver cells
was probably due to non-specific toxicity.
Response of WEHI-3b cells to IL-3
If WEHI-3b cells respond to extracellular IL-3, we
reasoned that actively-growing cells replaced in
fresh medium may suffer an extended early lag
period whilst sufficient IL-3 accumulates to
restimulate growth. We therefore compared cells
replaced in fresh medium with those in 50% of
their own conditioned medium, Figure 6. However,
this showed that there was no difference in the
early proliferative responses of cells with or without
added IL-3; the two curves were parallel and
almost superimposed. Over the first few hours of
re-culture, proliferation in both cultures decreased256 J.M. GARLAND et al.
Table IX Incubation ofWEHI-3b CM with liver cells; effect on IL-3 activity after 2 hoursa
% liver-conditionedmedium' in assay; cpm+s.d.
Conditioned medium Cell line assayed 25 12 6
Cell pellet 1Sal 10,640+1,275 24,159+ 154 40,113+1,989
Al.l.l.C2 13,007+1,751 15,460+2,265 17,018+1,266
100,00g pellet 15al 11,270+3,165 29,691 +2,519 47,605+5,776
Al.l.l.C2 12,496+1,104 17,840+ 1,466 18,793+1,217
100,00g S-N 1Sal 779+280 1,155+436 5,980+ 132
A1.1. .C2 976+ 116 13,524+373 20,874+653
Control, no liver cells lSal 45,290+ 1,044 58,169+457 6,669+6,107
Al.l.l.C2 19,155+369 20,617+50 18,781+613
aSimilar activities recovered after 18h incubation.
bOriginal IL-3 in the conditioned media; concentration was 12, 6 and 3% respectively in the assay.
0
0
0 5 10 20
Time (h)
Figure 6 Proliferation of WEHI-3b cells after transfer
to fresh medium with and without IL-3. Initial
viabilities were 99%, and T = 0 incorporation
18,000 cpm.
significantly; after 24h in fresh medium
proliferation had increased, and logarithmic growth
started; but cells replaced in the conditioned
medium were still depressed. Viability in both
cultures paralleled the thymidine uptake, but the
effect was much less; the maximum drop was not
more than 25% at 2h (data not shown).
Discussion
The purpose of these studies was to determine the
presence of IL-3 in vivo and the fate of IL-3
dependent cell lines. Parallels exist for other
haemopoietic growth factors, for example, G/M
CSF and TCGF. CSF is elaborated in vivo, as it is
readily obtained frqm sources such as urine and
serum (Moore et al., 1974; Das et al., 1981; Burgess
& Metcalf, 1980), although injected CSF has a
short life (Shadduck et al., 1980). Additionally,
radiolabelled CSF has some affinity for the
haemopoietic tissue on which it acts
(Shadduck et al., 1980). In terms of target cells,
CSF promotes both proliferation and differentiation
of myeloid progenitors (Burgess & Metcalf, 1980)
such that functional cells are produced in vitro
(Gorczynski et al., 1980). Likewise, activated T-cells
have receptors for IL-2, which appears to be a
proliferation-mediator without differentiating ability
(Raulet & Bevan, 1982). Although much is now
known about cellular mechanisms related to IL-2
promoted proliferation in vitro (Maizel et al., 1981;
Sekaly et al., 1982), its production in vivo is still
uncertain; this may be related again to its short
half-life in vivo and the presence of inhibitors in
serum (Wagner et al., 1980; Bindon et al., 1982).
However, injection of IL-2 into immunodeficient
animals (nu/nu mice) appears to result in
establishment of T-cell like responses suggesting
that it may act physiologically (Wagner et al.,
1980); a similar conclusion has been made for the
myeloid differentiation factor described by Lotem
& Sachs (1981). Our experiments are different in
that we have used a constituitive (in vivo)
lymphokine-producing leukaemic cell line. We
found intracellular lymphokine in early leukaemic
liver nodules, and have shown that it is identical or
very closely similar to IL-3 produced in vitro.
Although we did not find it initially in
corresponding marrow or spleen lysates, nor in
serum, its presence intracellularly in spleens from
terminal leukaemic mice suggests that the problem
in earlier lysates is logistical; the amount in vivo is
considerably less than in a corresponding number
of cells grown in vitro. Further, the intracellular
presence of IL-3 is correlated with the presence of
potent inhibitors which mask its activity in vitro
and suppress other cells. This may be relevant to
the requirement for a minimal number of WEHI-3b
cells to induce leukaemia, and the long latent
period before the leukaemia becomes overt; in vitro,
the mass-generation time of WEHI-3b cells is aboutIL-3 AND FDCP IN VIVO 257
18h, and at this proliferation rate a 15-day
leukaemic mouse would greatly exceed its own
body-weight in leukaemic cell load.
Our experiments thus show conclusively that IL-3
is not an in vitro artifact; and suggest that its
production may be related to the leukaemic state.
Thus, the factor (or a group of very similar ones)
promotes many cell lineages in vitro (Garland &
Dexter, 1982b; Bazill et al., 1983; Garland &
Crompton, 1983; Iscove et al., 1982) and
"immortalises" cell lines with characteristics of the
WEHI-3b leukaemic line (Dexter et al., 1980).
"Misplaced" elaboration of IL-3 internally could
therefore be a universal route to leukaemia
induction within a range of haemopoietic cells. In
WEHI-3b cells, such a mechanism does not appear
to involve surface receptors, as if actively-growing
WEHI-3b cells are replated in WEHI-3b CM, there
is no enhancement of proliferation compared to
controls without WEHI-3b CM; both cultures
suffer equal falls in [3H]dT incorporation before
growth is resumed. The reason for the initial fall is
not clear; we have consistently observed a similar
effect in FDCP replated in fresh medium with IL-3,
and it appears to be related to the physical
manipulation of the cells. The apparent continuing
depression in the culture with conditioned medium
does not seem to be entirely explicable on medium
quality (50% conditioned medium) as firstly, the
cells were actively growing in it at 100% and
secondly, the dilution by fresh medium should have
allowed at least one doubling over 18 to 20h
(maximum culture density of WEHI-3b cells is
.-22x 106 cellsml ').
In contrast to le7ukaemic mice, in vitro culture of
lymphocytes activated in vivo by GVH reactions is
not associated with IL-3 production. This is
somewhat surprising as in early GVH reactions a
significant component of the proliferation is host
cell (Ford et al., 1981), presumably mediated by
soluble factors in vivo (English, 1982). With regard
to the inability to recover FDCP after in vivo
injection, the recirculation and co-culture
experiments suggest that one major problem is non-
specific cell toxicity generated by normal cells e.g.
liver, in vitro. Thus, the nuntber of normal cells
needed to be harvested to ensure adequate
representation of FDCP cells is more than sufficient
to inhibit their growth; in addition IL-3 is rapidly
cleared in vivo and FDCP are sensitive to factor
withdrawal (Garland & Dexter, 1982b). The most
likely explanation is therefore that FDCP neither
proliferate nor survive long enough to recover.
However, there is a report of similar WEHI-3b CM
dependent lines maturing in vivo in diffusion
chambers (Greenberger et al., 1980). It therefore
seems paradoxical that FDCP lines can be
generated at all; all the lines have been derived
from long-term marrow cultures, which are
defective in T-cells (Phillips, 1980; Schrader et al.,
1979). Marrow cultures do not elaborate detectable
levels of IL-3 but can be induced to do so if T-cells
are supplied (J. Garland, in preparation). If the
lines are absolutely dependent on IL-3, then either
IL-3 is elaborated at micro-levels in the cultures, in
a manner similar to G/M CSF (Shadduck et al.,
1980), or FDCP represent lines that do not
normally arise but are "diverted" to IL-3
dependency by culture selection. This seems
unlikely as firstly, IL-3 which is very closely similar
if not identical to HCGF, promotes other
recognisable cell lineages in vitro (Bazill et al., 1982;
Garland & Crompton, 1982), and secondly, other
cell lines dependent on added factors can function
in vivo as in the case of cloned NK lines (Warner &
Dennert, 1982). Apparently, GVH mice do have
increased numbers of IL-3 promoted progenitors (J.
Schrader, personal communication) and studies to
determine the fate of IL-3 dependent lines in
WEHI-3b leukaemic mice are in progress.
Finally, although FDCP do not seem to be
related to T-cells themselves, they respond to a T-
cell associated factor and it is tempting to speculate
that one set of T-cell functions may be to assist in
the regulation of haemopoiesis, unrelated to their
undoubted function in immunity. Support for the
notion can be found in numerous examples of T-
cell help for proliferation of CFUs and indeed the
establishment of long-term haemopoietic cultures
(Sharp et al., 1981; Dexter et al., 1977).
Our conclusions are that IL-3 is not an in vitro
artifact and that it may be related to the leukaemic
potential of WEHI-3b cells. Problems still remain
with identifying the factor as a physiological
haemopoietic regulator, but the construction of
genetic probes and antibodies to it offers a fruitful
direction to pursue.
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